[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"oesophageal-adenocarcinoma\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:oesophageal-adenocarcinoma":26},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,6,0,[8,47,80,118,145,175],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":18,"targetDuration":4,"studyType":21,"phases":22,"briefSummary":24,"conditions":25,"keywords":30,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":35,"lastUpdatePostDateStruct":36,"startDateStruct":39,"completionDateStruct":41,"leadSponsor":43,"locationsCount":46},"100621807","will-a-pre-therapy-exercise-intervention-improve-the-outcomes-of-patients-with-advanced-oesophageal-cancer-100621807",false,"NCT07375420","Will a Pre-therapy Exercise Intervention Improve the Outcomes of Patients With Advanced Oesophageal Cancer?","Optimising Prehabilitation Exercise to Enhance Tumour Outcomes in Advanced Oesophageal Cancer","OPTIMUS","Inclusion Criteria:\n\n* Adults with resectable oesophageal adenocarcinoma who are planned for neoadjuvant chemotherapy followed by surgery\n\nExclusion Criteria:\n\n* Inability to carry out CPET or exercise due to underlying health conditions\n* pregnancy\n* \\\u003C18 years old","ALL",{"count":19,"type":20},50,"ESTIMATED","INTERVENTIONAL",[23],"NA","Background\n\nRegular exercise can significantly improve physical and mental health during cancer treatment and reduce the time needed in the hospital. Animal studies suggest that exercise training can also reduce the number of cancer cells. For example, exercise training in mice produces more immune cells in the tumour. These immune cells in the tumour contribute to the destruction and reduction of the size of the tumour and are a vital component of effective immunotherapy (cancer treatment that helps the immune system fight cancer).\n\nIn humans, exercise training and the immune response in tumours are less understood. Only 1 study has investigated the effect of a single exercise session before surgical removal of the prostate in prostate cancer patients. As the benefits of exercise are gained from weeks\u002Fmonths of exercise, no effect on the immune cells in the tumours were found.\n\nThe investigators have carried out a previous study looking at how exercise affects fitness before major surgery. After this they used state-of-the-art methods to detect and visualise immune cells within the tumour. Compared with the patients who did not exercise, the exercise group had significantly more immune cells in their tumours, consisting of a group of cells that are important for killing cancerous cells called CD8+ T cells. CD8+ T cells in tumours are associated with improved survival outcomes.\n\nImportantly, they found a link between changes in fitness and the amount of these cells in the tumour. This suggests that if there is increase in fitness, there also an increase in the frequency of these cells in the tumour. Therefore, the investigators propose performing a clinical trial to find out the best level of exercise patients need to sustain before surgery to produce this improved immune response.\n\nThe trial will aim to understand how this happens and how the entry of immune cells into the tumour changes the environment around a tumour. The investigators consist of a team of exercise immunologists, tumour immunologists and clinicians working with the Human Performance Institute at the University of Surrey in collaboration with the Royal Surrey NHS Trust.\n\nHow it will be done\n\nThe investigators will assess immune cell response in blood samples obtained from oesophageal cancer patients before, during and after a high or low intensity exercise programme. Following the exercise programme, tumour tissue removed at surgery from these patients will be used to investigate the the presence and quantity of these immune cells.\n\nPotential impact\n\nA better understanding of this is important, as current anti-cancer immune-based therapeutics work best when there is a an immune response within the patient's tumour. Generating evidence that exercise can improve the immune response against the tumour in patients with oesophageal cancer would provide significant justification for introducing \"personalised\" exercise programmes to improve treatment outcomes.",[26,27,28,29],"Oesophageal Adenocarcinoma","T Cells","Tumor Microenvironment","Exercise",[31,32,33],"oesophageal cancer","exercise","tumour microenvironment","RECRUITING","2026-01-29",{"date":37,"type":38},"2026-02-02","ACTUAL",{"date":40,"type":38},"2024-04-26",{"date":42,"type":20},"2028-10-30",{"name":44,"class":45},"University of Surrey","OTHER",1,{"id":48,"slug":49,"hasResults":11,"nctId":50,"briefTitle":51,"officialTitle":52,"acronym":53,"eligibilityCriteria":54,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":56,"targetDuration":58,"studyType":59,"phases":4,"briefSummary":60,"conditions":61,"keywords":65,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":46},"100619380","multicenter-prospective-cohort-on-esophageal-endoscopic-submucosal-dissection-100619380","NCT07343869","Multicenter Prospective Cohort on Esophageal Endoscopic Submucosal Dissection","Prospective Multicenter Cohort on Esophageal Submucosal Dissection: Evaluation of Technical, Oncological, and Organizational Outcomes in Real-Life Practice","FEO","Inclusion Criteria:\n\n* Adults (≥ 18 years old)\n* Patients referred for endoscopic resection of an esophageal lesion and treated by submucosal dissection\n* Patients managed in one of the participating centers\n* Patient who has received oral and written information about the study and has not objected to participation\n* Patients covered by a social security or health insurance scheme.\n\nExclusion Criteria:\n\n* Patient refusal after reading the information sheet\n* Patient under legal protection (guardianship, curatorship, court-ordered protection)\n* Inability to inform the patient due to cognitive impairment, language barrier, or medical emergency\n* Patients previously included for another lesion in the same study\n* Pregnant or breastfeeding women.\n* Patient deprived of liberty.\n* Patient currently enrolled in another clinical trial.","18 Years",{"count":57,"type":20},750,"5 Years","OBSERVATIONAL","In France in 2018, there were an estimated 2,074 new cases of esophageal adenocarcinoma and 3,224 cases of squamous cell carcinoma. The estimated deaths from esophageal cancer were 3,725, with a standardized 5-year net survival rate of 20% for cases diagnosed between 2010 and 2015, mainly due to late diagnosis.\n\nSurgery was historically the standard treatment for localized disease but carries significant morbidity. Over the past decade, endoscopic treatments, particularly endoscopic submucosal dissection (ESD), have become the reference approach for superficial esophageal cancers.\n\nAfter endoscopic resection, histological analysis allows classification of recurrence risk into very low, low, and high categories. Predicting lymph node or distant recurrence is complex, depending on factors such as depth of wall infiltration, lymphovascular invasion, and tumor differentiation. The frequent combination of unfavorable histological features may have led to an overestimation of lymph node involvement risk in T1b cancers.\n\nESD is widely performed in France, with over 1,600 procedures reported in 2023 for esophageal and gastric lesions, demonstrating the feasibility of a large observational study.\n\nThis multicenter French cohort will evaluate technical, oncological, and organizational outcomes of esophageal ESD, including overall survival, recurrence-free survival, and management of residual Barrett's esophagus. It will also identify predictive factors for treatment success, recurrence, and complications, providing real-world evidence to guide patient management.",[62,26,63,64],"Superficial Esophageal Cancer","Oesophageal Squamous Cell Carcinoma","Barretts Esophagus With Dysplasia",[66,67,68,69],"Endoscopic esophageal disection","Endoscopic resection","Endoscopic submucosal dissection","Curative resection","NOT_YET_RECRUITING","2026-01-07",{"date":73,"type":38},"2026-01-15",{"date":75,"type":20},"2026-02-01",{"date":77,"type":20},"2036-02-01",{"name":79,"class":45},"Société Française d'Endoscopie Digestive",{"id":81,"slug":82,"hasResults":11,"nctId":83,"briefTitle":84,"officialTitle":84,"acronym":85,"eligibilityCriteria":86,"healthyVolunteers":87,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":88,"targetDuration":90,"studyType":59,"phases":4,"briefSummary":91,"conditions":92,"keywords":100,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":109,"lastUpdatePostDateStruct":110,"startDateStruct":112,"completionDateStruct":114,"leadSponsor":116,"locationsCount":4},"100612988","augmented-response-of-volatile-biomarkers-in-the-assessment-of-oesophagogastric-cancer-aroma2-100612988","NCT07260734","AUGMENTED RESPONSE OF VOLATILE BIOMARKERS IN THE ASSESSMENT OF OESOPHAGOGASTRIC CANCER (AROMA2)","AROMA2","Inclusion Criteria:\n\n* Aged ≥ 18 years old.\n* Participants referred from primary care according to the urgent suspected cancer referral guidelines for potential underlying oesophagogastric cancer a for the reference test (described below).\n* Willing and able to provide informed written consent to take part in study.\n\nExclusion Criteria:\n\n* Previous oesophageal or gastric resection\n* History of cancer within three years (other than non-melanoma skin cancers)\n* Co-morbidities preventing breath collection\n* Pregnant participants\n* Allergies to any of the constituents of the nutrient drink including glucose, glycerol, iron sulphate, Maltodextrin (Corn, Potato), Xanthan Gum, Potassium Chloride, tyrosine, phenylalanine, and glutamic acid\n* Unable or unwilling to provide informed written consent.",true,{"count":89,"type":20},6000,"3 Months","Cancer of the stomach and oesophagus is among the world's top five cancers. Survival rates are very poor as the disease presents late and early symptoms are non-specific. The study team has developed a non-invasive test for cancers of the stomach and oesophagus based on the detection of volatile organic compounds in exhaled breath. These compounds are known to be produced by both cancers as well as cancer associated bacteria within the gut.\n\nThe proposed innovation is to improve the accuracy of this test by investigating whether simple metabolic substrates can increase the production of these volatile organic compounds by both the tumour and its associated bacteria.",[93,26,94,95,96,97,98,99],"OESOPHAGO-GASTRIC CARCINOMA","Gastric Adenocarcinoma and Gastroesophageal Junction Adenocarcinoma","Oesophageal Cancer Nos","Oesophageal Cancer","Oesophageal Junction Cancer","Breath Tests","Volatile Organic Compound",[101,102,103,104,105,106,107,108],"Oesophageal adenocarcinoma","Gastric adenocarcinoma","Breath testing","Microbiome","Augmentation","Volatile Organic Compounds","Volatilomics","Breathomics","2025-11-21",{"date":111,"type":38},"2025-12-03",{"date":113,"type":20},"2025-12-01",{"date":115,"type":20},"2028-11-01",{"name":117,"class":45},"Imperial College London",{"id":119,"slug":120,"hasResults":11,"nctId":121,"briefTitle":122,"officialTitle":123,"acronym":124,"eligibilityCriteria":125,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":126,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":128,"conditions":129,"keywords":133,"overallStatus":70,"whyStopped":4,"lastUpdateSubmitDate":136,"lastUpdatePostDateStruct":137,"startDateStruct":139,"completionDateStruct":141,"leadSponsor":143,"locationsCount":4},"100605222","evaluation-of-seismocardiographyscg-for-assessing-fitness-and-predicting-outcomes-in-oesophageal-cancer-surgery-100605222","NCT07159711","Evaluation of Seismocardiography(SCG) for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery","Evaluation of Seismocardiography (SCG) as a Tool for Assessing Fitness and Predicting Outcomes in Oesophageal Cancer Surgery","SEISMIC","Inclusion Criteria:\n\n* Age \\>=18\n* Diagnosis of Oesophageal cancer (T0-4 N0-3 M0, Oesophageal \u002F Gastro-Oesophageal Junction (GOJ) type 1-2 adenocarcinoma\n* Patients being considered for curative treatment (i.e. due to undergo NAC and Oesophagectomy \u002F Oesophago-Gastrectomy \\[open \u002F MIO \u002F hybrid \u002F robotic\\])\n* Patients able to give informed consent\n\nExclusion Criteria:\n\n* Pregnant patients.\n* Patients under the age of 18.\n* Patients undergoing primary Oesophagectomy +\u002F- Oesophago-Gastrectomy with no neoadjuvant therapy.\n* Patients undergoing Neoadjuvant chemoradiotherapy.\n* Patient's being treated with curative intent for Oesophageal Squamous cell carcinoma\n* Patients that are deemed not fit or suitable for Oesophagogastric cancer resection as part of a Multi-Disciplinary Team meeting decision.\n* Patients with implanted devices such as pacemakers or cardioverter-defibrillators.",{"count":127,"type":20},164,"Oesophageal cancer is a common cause of cancer death worldwide. Curative treatment involves chemotherapy and surgery but has significant risks. Therefore, patient selection and improving physical fitness to withstand such major treatment is important to reduce the risk of complications. Physical fitness is traditionally measured by a specialised exercise test called Cardiopulmonary exercise testing (CPET), which can take up to one hour and requires specialised staff and expensive equipment such as a graded exercise bike or treadmill. Seismofit is a small device (smaller than a smartphone) used to estimate fitness in patients in under three minutes while lying down at rest. It measures the vibrations generated by the heart and, together with patient height, weight, age, and gender, accurately estimates fitness using an algorithm developed in healthy patients. The device has never been tested in a large group of oesophageal cancer patients to see if it can be used to predict complications in patients undergoing cancer treatment.\n\nIn this study, patients undergoing Oesophageal cancer treatment with chemotherapy or chemoradiotherapy and surgery will have Seismofit measurements at various points during their treatment to see if we can predict complications and hospital stay. Secondly, this study will also evaluate the accuracy of Seismofit compared to the gold standard CPET results in cancer patients.",[96,26,130,131,132],"Prehabilitation","Oesophagectomy","Neoadjuvant Chemotherapy",[31,131,134,130,135],"Fitness","Neoadjuvant chemotherapy","2025-08-29",{"date":138,"type":38},"2025-09-08",{"date":140,"type":20},"2025-09-15",{"date":142,"type":20},"2027-06",{"name":144,"class":45},"Guy's and St Thomas' NHS Foundation Trust",{"id":146,"slug":147,"hasResults":11,"nctId":148,"briefTitle":149,"officialTitle":150,"acronym":151,"eligibilityCriteria":152,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":4,"enrollmentInfo":153,"targetDuration":4,"studyType":21,"phases":155,"briefSummary":157,"conditions":158,"keywords":159,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":165,"lastUpdatePostDateStruct":166,"startDateStruct":168,"completionDateStruct":170,"leadSponsor":172,"locationsCount":174},"100568948","phase-2-metformin-as-a-metabolic-intervention-in-oesophageal-adenocarcinomas-to-improve-response-to-neoadjuvant-chemoradiotherapy-100568948","NCT06687876","Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy","Metformin as a Metabolic Intervention in Oesophageal Adenocarcinomas to Improve Response to Neoadjuvant Chemoradiotherapy.","MEMENTO","Inclusion Criteria:\n\n* Surgical resectable (\\\u003CT4b, N0 or N+, M0), and histologically proven adenocarcinoma of the oesophagus or gastro-oesophageal junction planning to undergo neoadjuvant chemoradiotherapy.\n* Adult patients (age ≥ 18 years).\n* ECOG performance status 0 or 1 (cf. Appendix A).\n* Adequate hematological, renal and hepatic functions defined as:\n\n  * Absolute Neutrophil Count ≥ 1.5 x 10\\^9\u002FL\n  * Platelets ≥ 100 x 10\\^9\u002FL\n  * Hemoglobin ≥ 5.6 mmol\n  * Total bilirubin ≤ 1.5 x upper normal limit\n  * Creatinine clearance (Cockroft) \\> 30 ml\u002Fmin\n* Patients must be willing to undergo two endoscopies for investigational purposes.\n* Written, voluntary informed consent.\n* Patients must be accessible to follow up and management in the treatment center.\n\nExclusion Criteria:\n\n* Patients diagnosed with diabetes mellitus type 1 or 2 receiving anti-diabetic drugs.\n* Patients prescribed metformin or another anti-diabetic drug for any reason.\n* Patients allergic or intolerant to metformin.\n* Excessive alcohol consumption.\n* Use of OCT1\u002FOCT2 inhibitors (e.g. verapamil, cimetidine, dolutegravir, isavuonazol, trimethoprim, vandetanib, crizotinib and Olaparib).\n* Use of OCT1\u002FOCT2 inducers (e.g. rifampicine).\n* Use of immunosuppressive medication (corticosteroids, cyclosporine, tacrolimus, sirolimus, everolimus, cyclophosphamide).\n* Previous systemic therapy or radiotherapy on the oesophagus.\n* Severe renal impairment (CLcr ≤ 30 ml\u002Fmin).\n* Past (within 5 years) or current history of malignancy other than entry diagnosis interfering with prognosis of oesophageal cancer.\n* Previous systemic therapy for other forms of cancer within the last six months.\n* Patients with prior allogeneic stem cell or solid organ transplantation\n* Pregnancy (positive serum pregnancy test), planning to become pregnant, and lactation.\n* Clinically significant cardiovascular disease (including myocardial infarction, unstable angina, symptomatic congestive heart failure, serious uncontrolled cardiac arrhythmia) precluding major surgery.\n* Pulmonary fibrosis, active, non-infectious pneumonitis and\u002For severely impaired lung function precluding major surgery and\u002For radiation.\n* Serious underlying medical condition which would impair the ability of the patient to receive the planned treatment, including prior allergic reactions to drugs containing Cremophor, such as teniposide or cyclosporine.\n* Dementia or altered mental status that would prohibit the understanding and giving of informed consent.",{"count":154,"type":20},14,[156],"PHASE2","The primary objective of this study is to investigate whether two weeks of metformin treatment can activate the tumour microenvironment in patients with stage II and III oesophageal adenocarcinomas.",[26,28],[160,161,31,162,163,164],"metabolic intervention","adenocarcinoma","metformin","tumor microenvironment","neoadjuvant chemoradiotherapy","2025-07-09",{"date":167,"type":38},"2025-07-10",{"date":169,"type":38},"2025-03-09",{"date":171,"type":20},"2030-12",{"name":173,"class":45},"Amsterdam UMC, location VUmc",2,{"id":176,"slug":177,"hasResults":11,"nctId":178,"briefTitle":179,"officialTitle":180,"acronym":181,"eligibilityCriteria":182,"healthyVolunteers":11,"sex":17,"minAge":55,"maxAge":183,"enrollmentInfo":184,"targetDuration":4,"studyType":59,"phases":4,"briefSummary":186,"conditions":187,"keywords":4,"overallStatus":34,"whyStopped":4,"lastUpdateSubmitDate":189,"lastUpdatePostDateStruct":190,"startDateStruct":192,"completionDateStruct":194,"leadSponsor":196,"locationsCount":46},"100538326","longitudinal-assessment-of-biomarkers-after-oesophagogastric-cancer-surgery-100538326","NCT06289374","Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery","The LABS Study: Longitudinal Assessment of Biomarkers After Oesophagogastric Cancer Surgery (BIORESOURCE 2: Longitudinal)","LABS","Inclusion Criteria:\n\n* Aged 18-90 years at the time of initial recruitment\n* Gastric\u002Foesophageal adenocarcinoma cohort (biopsy proven adenocarcinoma) recruited into BIORESOURCE 1\n\nExclusion Criteria:\n\n* Oesophageal squamous cell carcinoma\n* Previous oesophageal and gastric resection\n* History of another cancer within five years. If a new other cancer type is diagnosed within the sampling time frame, no further samples will be taken.\n* Participants with co-morbidities preventing breath collection\n* Unable or unwilling to provide informed written consent\n* Pregnant women","90 Years",{"count":185,"type":20},100,"Oesophagogastric cancer (cancer of the gullet and stomach) is the fifth most common cancer in England and Wales with 16,000 new cases diagnosed every year. Survival rates are poor with only 15% surviving beyond 5 years. There is also increasing research to understand the cancer biology and factors allowing cancers to progress. It is likely there is a relationship between the cancer-specific microbiome, cells related to inflammation, which promotes cancer progression. The BIORESOURCE 1 study has established a comprehensive resource of matched samples from patients with oesophageal and gastric cancer. This longitudinal study aims to obtain further matched biosamples in the follow-up period after cancer surgery to find biomarkers that may predict treatment response, recurrence and\u002For long term prognosis.",[26,188],"Gastric Adenocarcinoma","2025-02-17",{"date":191,"type":38},"2025-02-19",{"date":193,"type":20},"2025-02",{"date":195,"type":20},"2029-06",{"name":117,"class":45}]